Medigene AG reports Financial Results and Business Update for Q3 2024
24 oct. 2024 01h30 HE
|
Medigene AG
Planegg/Martinsried, October 24, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene will Present at ASGCT 2024 and Host R&D Event
02 oct. 2024 09h00 HE
|
Medigene AG
Planegg/Martinsried, October 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024
14 sept. 2024 07h30 HE
|
Medigene AG
Planegg/Martinsried, September 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...